Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

about

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

Item

http://www.wikidata.org/entity/Q57173000

description

scientific article published on 09 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@en

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@nl

type

Item

label

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@en

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@nl

prefLabel

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@en

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@nl

P1476

Speed of Adoption of Immune Ch ...... ice vs Pivotal Clinical Trials

@en

P2093

Amy P Abernethy

http://www.w3.org/2001/XMLSchema#string

Anne C Chiang

http://www.w3.org/2001/XMLSchema#string

Carolyn J Presley

http://www.w3.org/2001/XMLSchema#string

Cary P Gross

http://www.w3.org/2001/XMLSchema#string

Emily S Yin

http://www.w3.org/2001/XMLSchema#string

Jean Steiner

http://www.w3.org/2001/XMLSchema#string

Jeremy M O'Connor

http://www.w3.org/2001/XMLSchema#string

Kathi Seidl-Rathkopf

http://www.w3.org/2001/XMLSchema#string

Kenneth R Carson

http://www.w3.org/2001/XMLSchema#string

Kerin B Adelson

http://www.w3.org/2001/XMLSchema#string

P2860

The answer is 17 years, what is the question: understanding time lags in translational research

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Opportunities and challenges in leveraging electronic health record data in oncology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.

P304

e180798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAONCOL.2018.0798

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joseph S. Ross

Kristen Fessele

P577

2018-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29800974

http://www.w3.org/2001/XMLSchema#string

P932

6143052

http://www.w3.org/2001/XMLSchema#string